Read + Share
Amedeo Smart
Independent Medical Education
Al-Janabi A, Warren RB. Risankizumab versus adalimumab for moderate-to-severe plaque psoriasis: a critical appraisal. Br J Dermatol 2020 Jan 3. doi: 10.1111/bjd.18856.PMID: 31899817
Email
LinkedIn
Facebook
Twitter
Privacy Policy